IBJNews

Lilly wins temporary ban on sales of Strattera copies

Back to TopCommentsE-mailPrintBookmark and Share
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, convinced a judge to temporarily block generic versions of its attention-deficit treatment Strattera while the company considers an appeal of an earlier patent ruling

U.S. District Judge Dennis M. Cavanaugh issued the order Thursday, giving Lilly time to weigh its options following his Aug. 12 ruling that invalidated a patent on the medicine. The order ends 14 days after the judge signs a final judgment in that case, unless the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., decides it should last through the appeal.

The invalidation of Lilly’s Strattera patent opened the door for generic copies by as many as 10 companies, including Mylan Inc., Teva Pharmaceutical Industries Ltd. and Novartis AG’s Sandoz unit. Strattera, known by its active ingredient atomoxetine, generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder, Lilly said in a fourth-quarter earnings statement. The Indianapolis-based company reported $21.8 billion in total annual revenue.

Lilly’s patent on Strattera would have prevented sales of copies until May 2017. The company said after the Aug. 12 ruling that it expects “near-term entry” of generic versions and reduced its sales-growth forecast for the year to the low- to mid-single digits, from the mid-single digits.

The company’s top-selling drugs Zyprexa and Cymbalta, which account for more than a third of its revenue, face generic competition by 2013. Zyprexa is used to treat schizophrenia and Cymbalta is an antidepressant.

Lilly shares dropped 44 cents, or 1.3 percent, to $34.35 each in midday trading. The shares fell 2.6 percent this year before Thursday.

A U.S. appeals court on July 28 upheld a ruling that a patent on Lilly’s cancer medicine Gemzar was invalid. The decision may allow generic competition as early as November, two years earlier than Lilly had projected. Gemzar had $747.4 million in U.S. sales last year.

Mylan, based in Canonsburg, Pa., is the largest generic-drug maker based in the U.S. Petah Tikva, Israel-based Teva Pharmaceutical is the world’s biggest, followed by Basel, Switzerland-based Novartis’s Sandoz unit.

The other generic-drug makers who had challenged the Strattera patent were Synthon BV; Iceland’s Actavis Group hf; Canada’s Apotex Inc.; and India’s Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd. and Cadila Healthcare Ltd.’s Zydus.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. From the story: "The city of Indianapolis also will consider tax incentives and funding for infrastructure required for the project, according to IEDC." Why would the City need to consider additional tax incentives when Lowe's has already bought the land and reached an agreement with IEDC to bring the jobs? What that tells me is that the City has already pledged the incentives, unofficially, and they just haven't had time to push it through the MDC yet. Either way, subsidizing $10/hour jobs is going to do nothing toward furthering the Mayor's stated goal of attracting middle and upper-middle class residents to Marion County.

  2. Ron Spencer and the entire staff of Theater on the Square embraced IndyFringe when it came to Mass Ave in 2005. TOTS was not only a venue but Ron and his friends created, presented and appeared in shows which embraced the 'spirit of the fringe'. He's weathered all the storms and kept smiling ... bon voyage and thank you.

  3. Not sure how many sushi restaurants are enough, but there are three that I know of in various parts of downtown proper and all are pretty good.

  4. First off, it's "moron," not "moran." 2nd, YOU don't get to vote on someone else's rights and freedoms that are guaranteed by the US Constitution. That's why this is not a state's rights issue...putting something like this to vote by, well, people like you who are quite clearly intellectually challenged isn't necessary since the 14th amendment has already decided the issue. Which is why Indiana's effort is a wasted one and a waste of money...and will be overturned just like this has in every other state.

  5. Rick, how does granting theright to marry to people choosing to marry same-sex partners harm the lives of those who choose not to? I cannot for the life of me see any harm to people who choose not to marry someone of the same sex. We understand your choice to take the parts of the bible literally in your life. That is fine but why force your religious beliefs on others? I'm hoping the judges do the right thing and declare the ban unconstitutional so all citizens of Wisconsin and Indiana have the same marriage rights and that those who chose someone of the same sex do not have less rights than others.

ADVERTISEMENT